Information Density: REMICADE® (Johnson & Johnson) – Signal Evidence & AI Readability

REMICADE® (Johnson & Johnson)

(https://remicade.com) 📸 Data Snapshot: June 19, 2026
Information Density — The Lens

Classify each sentence as substantive or hollow. Grounding markers — numbers, currencies, dates, technical units, named entities — outweigh marketing adjectives. When fluff sits right next to hard evidence, the fluff is forgiven.

Info Density Power-words vs. Substance ratio.
27 Impact Weight: 30 / 100
90% Reputation

Information density is exceptionally high for a consumer-facing site. Headings like H2 ‘I am CURRENTLY being treated with REMICADE®’ are functional rather than promotional. The body text contains zero power-word fluff, instead providing a granular list of eight specific therapeutic areas including ‘active ankylosing spondylitis’ and ‘chronic severe plaque psoriasis.’ The substance-to-fluff ratio is high due to the clinical specificity of the indications listed.

Information Density is read straight from the body copy: how much of the text carries grounded, checkable substance versus hollow filler. Below is the clean text the engine analyzed, then the industry’s known generic-claim patterns to weigh it against.

📝 The Narrative — clean text per page (the substance-vs-filler signal)
HOMEPAGE (https://remicade.com) Official Consumer Website for REMICADE® (infliximab) | REMICADE®
[H2] I am CURRENTLY being treated with REMICADE®
Your treatment choice. Being asked to switch. Support to stay on therapy.
Get information

[H2] I am starting treatment with REMICADE®
Learn about REMICADE®. How REMICADE® works. Paying for therapy.

Learn more
Adult: moderately to severely active Crohn’s disease
Pediatric: moderately to severely active Crohn's disease
Adult: moderately to severely active ulcerative colitis
Pediatric: moderately to severely active ulcerative colitis
Adult: moderately to severely active rheumatoid arthritis
Adult: active psoriatic arthritis
Adult: active ankylosing spondylitis
Adult: chronic severe plaque psoriasis

[H2] Patient resources

[IMG: Money Icon]

Find cost support options to help make treatment more affordable.

LEARN ABOUT COST SUPPORT OPTIONS

[IMG: Headset Icon]

See how our J&J withMe Care Coordinators can help you start, stay, and save on REMICADE®.

Customized support from a J&J withMe care coordinator

[IMG: Location Icon]

See treatment locations that are close to your home or workplace.

Find an infusion center

[IMG: Magazine Icon]

Get more information about REMICADE® and listen to other patients describe their treatment experiences.

Resources for you
1289 chars
🧭 Industry Context — common generic-claim patterns in Medical Devices, Pharma & Biotech to weigh the text against
Generic Claims: advancing human health, breakthrough innovation, life-changing therapies, transforming patient outcomes, pioneering medical science, the future of medicine…
Red Flags: FDA cleared used interchangeably with FDA approved, clinical claims without published study citations, breakthrough claims for incremental improvements, regulatory status implied but not specified, patient testimonials making efficacy claims, off-label promotion signals…
Semantic Drift Patterns: homepage claims breakthrough but pipeline page shows preclinical only, FDA approved claims but only for one indication, marketed broadly, claims clinical evidence but links to poster presentations not published studies, claims global reach but regulatory approvals are single-market…
Proof Expectations: specific regulatory clearance numbers (FDA 510(k), CE, TGA), published clinical trial results with ClinicalTrials.gov registration, ISO 13485 and GMP certification details, peer-reviewed publication citations, specific patent numbers and status, pharmacovigilance and adverse event reporting mechanisms…
Explore the other reputation pillars for REMICADE® (Johnson & Johnson)